HUTCHISON CHINA/S (NASDAQ:HCM) Now Covered by Analysts at Macquarie

Analysts at Macquarie initiated coverage on shares of HUTCHISON CHINA/S (NASDAQ:HCM) in a research report issued to clients and investors on Friday, July 5th, MarketBeat.com reports. The firm set an “outperform” rating on the stock.

A number of other analysts have also weighed in on the stock. BidaskClub lowered shares of Waterstone Financial from a “hold” rating to a “sell” rating in a research note on Friday, June 21st. HSBC started coverage on shares of HUTCHISON CHINA/S in a research note on Wednesday, March 27th. They issued a “buy” rating on the stock. Finally, Zacks Investment Research upgraded shares of Hope Bancorp from a “sell” rating to a “hold” rating in a research note on Wednesday, April 17th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $25.41.

Shares of NASDAQ:HCM traded up $0.20 during midday trading on Friday, reaching $20.68. The company’s stock had a trading volume of 187,635 shares, compared to its average volume of 742,504. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -36.28 and a beta of 0.70. HUTCHISON CHINA/S has a twelve month low of $19.37 and a twelve month high of $39.68. The firm has a fifty day moving average price of $24.22. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.33 and a quick ratio of 4.19.

A number of hedge funds have recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale grew its position in HUTCHISON CHINA/S by 1.9% during the first quarter. DekaBank Deutsche Girozentrale now owns 28,500 shares of the company’s stock valued at $840,000 after buying an additional 530 shares during the period. PNC Financial Services Group Inc. grew its position in shares of HUTCHISON CHINA/S by 748.9% in the first quarter. PNC Financial Services Group Inc. now owns 1,146 shares of the company’s stock valued at $36,000 after purchasing an additional 1,011 shares during the period. Krane Funds Advisors LLC grew its position in shares of HUTCHISON CHINA/S by 6.4% in the first quarter. Krane Funds Advisors LLC now owns 18,414 shares of the company’s stock valued at $563,000 after purchasing an additional 1,109 shares during the period. Baillie Gifford & Co. grew its position in shares of HUTCHISON CHINA/S by 0.6% in the fourth quarter. Baillie Gifford & Co. now owns 198,959 shares of the company’s stock valued at $4,594,000 after purchasing an additional 1,213 shares during the period. Finally, Macquarie Group Ltd. acquired a new stake in shares of HUTCHISON CHINA/S in the fourth quarter valued at about $46,000. Institutional investors own 21.00% of the company’s stock.

About HUTCHISON CHINA/S

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.

Further Reading: Golden Cross

Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.